The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge.

ABSTRACT: Breast cancer has the highest incidence among all malignancies diagnosed in women. Therapies have significantly improved over the years due to extensive molecular and clinical research; in a large number of cases, targeted therapies have provided better prognosis. However, one specific subtype remains elusive to targeted therapies-the triple-negative breast cancer. This immunohistochemically defined subtype is resistant to both endocrine and targeted therapies, leading to its poor prognosis. A field that is of great promise in current cancer research is epigenetics. By studying the epigenetic mechanisms underlying tumorigenesis-DNA methylation, histone modifications, and noncoding RNAs-advances in cancer treatment, diagnosis, and prevention are possible. This review aims to synthesize the

SUBMITTER: Temian DC 

PROVIDER: S-EPMC6158152 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature